Testing effectiveness (Phase 2)Not Yet RecruitingNCT07249554What this trial is testingCombination Therapy for Alcohol Use DisorderWho this might be right forAlcohol Use Disorder Johns Hopkins University 45
Very early researchLooking for participantsNCT06338553What this trial is testingGLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving TeplizumabWho this might be right forType 1 Diabetes Vanderbilt University Medical Center 24
Early research (Phase 1)Study completedNCT01272973What this trial is testingInvestigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male SubjectsWho this might be right forDiabetesDiabetes Mellitus, Type 2Healthy Novo Nordisk A/S 96
Not applicableStudy completedNCT01481675What this trial is testingDiabetes Resolution and Hormone Changes After BPDLL and LSGWho this might be right forDiabetes Mellitus University of Patras 24
Not applicableNot Yet RecruitingNCT07360457What this trial is testingGLP1 Analogues and the Risk of OsteoarthritisWho this might be right forOsteoarthritis Beni-Suef University 390
Not applicableNot Yet RecruitingNCT07288372What this trial is testingThe CGM-OGTT Glycemic Homeostasis StudyWho this might be right forType 2 DiabetesGlucose Metabolism Disorders Shanghai 6th People's Hospital 225
Not applicableLooking for participantsNCT07518407What this trial is testingDietary Insights and Nutritional Education in Adults on GLP-1 TherapyWho this might be right forObesity Type 2 Diabetes MellitusObesity University of South Carolina 50
Early research (Phase 1)Ended earlyNCT05671653What this trial is testingEvaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity RangeWho this might be right forObesity Pfizer 32
Not applicableLooking for participantsNCT06069622What this trial is testingRole of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist TreatmentWho this might be right forOverweight and Obesity Brigham and Women's Hospital 30
Not applicableStudy completedNCT07141472What this trial is testingGlucagon Like Peptide 1 (GLP-1) Booster™ RCT StudyWho this might be right forBlood Sugar; HighOverweight and ObesityFat Loss+2 more Lawry Han 69
Very early researchLooking for participantsNCT01803451What this trial is testingGlucagon-like Peptide 1, Glucose Metabolism and Gastric BypassWho this might be right forPost-bariatric Surgery The University of Texas Health Science Center at San Antonio 80
Post-approval studies (Phase 4)Not Yet RecruitingNCT07073053What this trial is testingThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential MechanismsWho this might be right forGlucagon-Like Peptide-1 Receptor AgonistsType 2 DiabetesCoronary Arterial Disease (CAD) Taipei Veterans General Hospital, Taiwan 60
Not applicableStudy completedNCT04738799What this trial is testingThe Impact of Food Order on Glycemic Excursions in Type 2 Diabetes Assessed by Continuous Glucose MonitoringWho this might be right forType 2 Diabetes Weill Medical College of Cornell University 20
Post-approval studies (Phase 4)Study completedNCT03985865What this trial is testingIG vs ID Bitter AdministrationWho this might be right forObesity Universitaire Ziekenhuizen KU Leuven 14
Post-approval studies (Phase 4)Active Not RecruitingNCT04892199What this trial is testingDoes GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?Who this might be right forMetabolic DisturbanceSchizophreniaType 2 Diabetes+3 more Anders Fink-Jensen, MD, DMSci 104